Australia as a base of research excellence
Some mid sized pharma and biotech companies still have limited experience running their clinical research outside the traditional regions within the US or Europe. The aim of this webinar is to highlight Australia's capability in early and late stage research. We will also discuss leveraging Australia’s R&D tax incentive to minimize the cost of these activities.
Australia is recognized as a Tier 1 country, consistently producing high quality data used for IND submissions and for registration with major regulatory bodies. The efficient regulatory pathway means that studies can begin quickly and certain exemptions, such as in cGMP manufacturing for Phase I trial materials, means that there is capacity for just-in-time preparation and quick start up. The Australian government encourages international medical and scientific research with a tax incentive program that allows cash refund of up to 45% of costs, and IP ownership that can be retained offshore if required.
Australia’s ability to produce high quality data is due to our vast pool of experienced research professionals, housed in excellent infrastructure; including dedicated Phase I units. This scenario extends across our KOLs, investigators, site staff, project managers and other clinical research professionals; most of whom have international experience with sponsors and collaborators.
Australia is a leader in the Asia Pacific region and plays an important role in Phase II – IV clinical trials. Asian countries are capable of recruiting large patent numbers with good quality data but processes and regulations are still highly diverse. Site experience levels are also inconsistent, therefore Australia's long history of guiding our Asian colleagues produces great dividends.
Join this webinar to understand how you can access Australia's expedited pathways, quality resources and infrastructure and experience in working with Asia.
Presented by
Marisa Petersen,
Managing Director, George Clinical
Marisa is the Managing Director of George Clinical, the clinical trial delivery arm of The George Institute for Global Health. Marisa completed her pharmacy degree at the University of Sydney and continued her studies with a PhD in Clinical Pharmacology and Pharmacokinetics.
Marisa has worked for over 20 years in the pharmaceutical industry, fulfilling roles in Regulatory Affairs, Clinical Research and Project Management. Prior to joining George Clinical, Marisa was the Vice President Asia Pacific for Omnicare Clinical Research, a global CRO, taking responsibility for the delivery of trials in the Asia-Pacific region and developing a network of offices across the region to effectively service customer needs. Marisa has a strong association with ARCS in Australia and Asia (an organisation similar to DIA in its goals) and is a member of the PIC R&D Taskforce.
Bev Thomas,
Chief Executive Officer, Nucleus Network
Bev is the CEO of Nucleus Network, Australia's leading Phase I clinical trials organisation. Prior to becoming CEO, Bev was responsible for Scientific Affairs at Nucleus Network. Bev is a registered pharmacist and has worked at Australian start-up companies and in Venture Capital since 1999, assisting with transitioning drug technologies into the clinic. Bev has a PhD in gene therapy from the University of Bath, post-doctoral experience in pharmaceutical formulation and a MBA in Technology Management.
Marc Peskett,
Director, MPR Group
Marc is an advisor to fast growing start-ups and entrepreneurial enterprises, specialising in venture planning, business and investment ready services, R&D Tax Incentive advice, funding, business structuring, financial analysis and modelling. His financial expertise and business advice has led to Marc being invited by clients to join their advisory boards. Participating on a number of clients' boards sees Marc adopting an active role in decision making and monitoring progress towards the achievement of long-term growth and profit objectives.